SCHEMBL563889

SCHEMBL563889

C=C=CCCCCCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.52
THRB P10828 1/20 0.42
FAAH O00519 2/20 0.41
TRPV1 Q8NER1 1/20 0.41
DNM1 Q05193 3/20 0.39
ALDH1A1 P00352 1/20 0.38
EP300 Q09472 1/20 0.37
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.36
KMT2A Q03164 1/20 0.36
GMNN O75496 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
APEX1 P27695 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1245228 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL564247 1.00
SCHEMBL9983408 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL5855710 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL25185965 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL11169476 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL25185997 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL969106 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL6297425 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1
SCHEMBL3212632 1.00 TSHR (0.52) TSHRTHRBFAAHTRPV1DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111205282-B ER protein modulators and uses thereof 上海科技大学 2023-12-01 CN disclosed
WO-2023085299-A1 CATIONIC LIPID 武田薬品工業株式会社 2023-05-19 WO disclosed
US-20220016102-A1 ER PROTEIN REGULATORS AND USE THEREOF SHANGHAITECH UNIVERSITY (CN) 2022-01-20 US disclosed
EP-2597932-B1 MANUFACTURING METHOD FOR ORGANIC LIGHT-EMITTING DEVICE SUMITOMO CHEMICAL CO (JP) 2021-04-14 EP disclosed
EP-2680672-B1 METHOD FOR PRODUCING ORGANIC ELECTROLUMINESCENT ELEMENT SUMITOMO CHEMICAL CO (JP) 2021-03-31 EP disclosed
EP-2485289-B1 LAMINATED STRUCTURE, POLYMER, ELECTROLUMINESCENT ELEMENT, AND PHOTOELECTRIC CONVERSION ELEMENT SUMITOMO CHEMICAL CO (JP) 2021-03-03 EP disclosed
EP-2478981-B1 SILVER-(CONJUGATED COMPOUND) COMPLEX SUMITOMO CHEMICAL CO (JP) 2020-12-23 EP disclosed
EP-2605621-B1 ORGANIC ELECTROLUMINESCENT ELEMENT AND METHOD OF PRODUCING SAME SUMITOMO CHEMICAL CO (JP) 2020-07-15 EP disclosed
CN-111205282-A ER protein modulators and uses thereof 上海科技大学 2020-05-29 CN disclosed
EP-2846374-B1 Layered structure SUMITOMO CHEMICAL CO (JP) 2019-11-06 EP disclosed
CN-1163224-C Medicine for improving excretion capacity of bladder ����ҩƷ��ҵ��ʽ���� 2004-08-25 CN disclosed
CN-1328451-A Medicine for improving excretion capacity of bladder TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-12-26 CN disclosed
EP-0696585-B1 NOVEL BISOXADIAZOLIDINE DERIVATIVE YAMANOUCHI PHARMA CO LTD (JP) 1998-12-16 EP disclosed
US-5643931-A ANTIDIABETIC AGENTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1997-07-01 US disclosed
EP-0696585-A1 NOVEL BISOXADIAZOLIDINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1996-02-14 EP disclosed
US-5039674-A Calcium antagonistics YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1991-08-13 US disclosed
US-4782160-A CALCIUM RECEPTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1988-11-01 US disclosed
EP-0276552-A1 1,4-dihydropyridine derivatives and their production YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-03 EP disclosed
US-RE31522-E COPOLYMERS OF DIAMINE-ENDCAPPED POLYOXYETHYLENE GLYCOLS AND A DICARBOXYLIC ACID; HYDRAULIC FLUIDS; METAL WORKING CINCINNATI MILACRON INC. (US) 1984-02-14 US disclosed
US-4374741-A LUBRICANTS, METAL WORKING, POLYETHER BLOCK POLYMERJ CINCINNATI MILACRON INC. (US) 1983-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016102-A1 ER PROTEIN REGULATORS AND USE THEREOF ESR2, ESRRG, ESRRA TSHR 2221/4885THRB 946/4885FAAH 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.